Holen Sie sich die Stockscreener-App
64.10
1.55%
-1.01
Handel nachbörslich:
63.76
-0.34
-0.53%
Schlusskurs vom Vortag:
$65.11
Offen:
$65.54
24-Stunden-Volumen:
1.53M
Relative Volume:
0.79
Marktkapitalisierung:
$7.50B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
21.23
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-7.07%
1M Leistung:
-15.44%
6M Leistung:
+11.09%
1J Leistung:
+22.96%
1-Tages-Spanne:
$63.78
$65.59
1-Wochen-Bereich:
$63.78
$68.83
52-Wochen-Spanne:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
64.10 | 7.62B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside - Forbes
What technical models suggest about Halozyme Therapeutics Inc.’s comebackWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Using data tools to time your Halozyme Therapeutics Inc. exitQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Heatmap analysis for Halozyme Therapeutics Inc. and competitors2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Tectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" Rating - MarketBeat
Key metrics from Halozyme Therapeutics Inc.’s quarterly data2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Portfolio - earlytimes.in
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current Valuation - Yahoo
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Halozyme Appoints New Chief Operating Officer - The Globe and Mail
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer - MarketScreener
Halozyme (HALO) Appoints New Chief Operating Officer - GuruFocus
Halozyme names Cortney Caudill as COO - TipRanks
Halozyme Therapeutics appoints Cortney Caudill as chief operating officer - Investing.com
Halozyme Therapeutics, Inc. Announces Appointment of Cortney Caudill as Senior Vice President and Chief Operating Officer, Effective October 1, 2025 - MarketScreener
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Nasdaq
Pattern recognition hints at Halozyme Therapeutics Inc. upsideEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
How buybacks impact Halozyme Therapeutics Inc. stock valueWeekly Trade Summary & Technical Pattern Based Signals - newser.com
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stock2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme Announces Merger Agreement with Elektrofi - TipRanks
Halozyme Therapeutics says if deal is terminated under certain circumstances, co to pay Elektrofi reverse termination fee of $36 million - MarketScreener
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Research Analysts Set Expectations for HALO FY2026 Earnings - MarketBeat
Institutional scanner results for Halozyme Therapeutics Inc.2025 Top Gainers & Daily Price Action Insights - newser.com
Is it too late to sell Halozyme Therapeutics Inc.Market Growth Summary & Free High Return Stock Watch Alerts - newser.com
Public Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Can volume confirm reversal in Halozyme Therapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - newser.com
Halozyme Therapeutics (NASDAQ:HALO) Shares Down 4.3% on Insider Selling - Defense World
What analysts say about Halozyme Therapeutics Inc RV7 stockStock Price Divergence & Small Investment Portfolio - earlytimes.in
Halozyme Acquires Elektrofi to Enhance Drug Delivery - MSN
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 4.3% on Insider Selling - MarketBeat
HC Wainwright Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $90.00 - MarketBeat
HC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
Halozyme stock price target raised to $90 from $85 at H.C. Wainwright - Investing.com
Halozyme eyes microparticles in $900m Elektrofi acquisition - Yahoo Finance
AMI Asset Management Corp Sells 16,475 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News - GuruFocus
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Connaughton of Halozyme sells $150k in stock By Investing.com - Investing.com Australia
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):